More recently, 4 major adjuvant trials of women with HER2+ early breast cancer (EBC) demonstrated that trastuzumab reduced 3-year breast cancer recurrence and risk of death rate by 50% [8]. The gene discussed is ERBB2; the disease is breast carcinoma.